|
FDA OKed Email Monitoring of CDRH Scientists, Senator Says
Lawmakers and watchdog groups are putting a brighter spotlight on the FDA, demanding the agency, HHS and the White House take action to ensure whistleblower protections and investigate allegations of inappropriate email monitoring by the drug regulator.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives